A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
Tanya T. Kwan(Howard Hughes Medical Institute), Shyamala Maheswaran(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Xin Hong(Southern University of Science and Technology), Mark Kalinich(Harvard University), Erin J. Silva(Massachusetts General Hospital), Ravi Kapur(Harvard University), Taronish D. Dubash(Harvard University), Aditya Bardia(UCLA Health), Daniel A. Haber(Howard Hughes Medical Institute), Uyen Ho(Harvard University), Joseph A. LiCausi(Harvard University), Ben S. Wittner(Broad Institute), Anita Giobbie‐Hurder(Institute for Tourism), Lecia V. Sequist(Harvard University), Mehmet Toner(Shriners Hospitals for Children - Erie), Tilak Sundaresan(Kaiser Permanente San Francisco Medical Center), David T. Miyamoto(Broad Institute)
Cited by 116
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k